Market Overview

UPDATE: Jefferies & Company Reiterates Underperform Rating, Lowers PT on VIVUS

Related VVUS
Neothetics' Fat Reduction Candidate Fails in Phase II Study
Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?

In a report published Wednesday, Jefferies & Company reiterated its Underperform rating on VIVUS (NASDAQ: VVUS), but lowered its price target from $13.00 to $6.00.

Jefferies noted, “VVUS disclosed shipped prescriptions of Qsymia on its 3Q12 earnings call. Actual demand is tracking 30% below IMS data, a surprise given our recent discussions with IMS on the tracking of Qsymia data. As a result, we are lowering our Qsymia estimates to reflect a linear extrapolation of recent demand trends and we are lowering our PT from $13 to $6.”

VIVUS closed on Tuesday at $11.82.

Latest Ratings for VVUS

Feb 2016RBC CapitalDowngradesOutperformSector Perform
Nov 2014Bank of AmericaMaintainsUnderperform
May 2014JP MorganMaintainsNeutral

View More Analyst Ratings for VVUS
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (VVUS)

View Comments and Join the Discussion!

Partner Center